HEMATOLOGICAL MALIGNANCIES: LEUKEMIAS, LYMPHOMAS AND MYELOMAS

VolverGo back

Resultados 80 results. LastUpdate Updated on 18/06/2021 [15:18:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Page1/4 nextPage   results/page


TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO MATRIPTASE ANTIBODIES

Publication No.: US2021177985A1 17/06/2021

Applicant:

UNIV RUTGERS [US]
UNIV GEORGETOWN [US]

US_2019358340_A1

Absstract of: US2021177985A1

The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase. In addition, administration of a matriptase antibody or immunoconjugates of a matriptase antibody and a cytotoxic agent in combination with administration of an immunomodulatory agent, such as thalidomide or an analog thereof, provides a more effective treatment of these cancers.

traducir

METHOD FOR TREATING ACUTE MYELOID LEUKEMIA

Publication No.: US2021177797A1 17/06/2021

Applicant:

BIONOMICS LTD [AU]

CN_111447972_A

Absstract of: US2021177797A1

The present invention relates to a method for the treatment of acute myeloid leukemia (AML) with medicaments useful for same. The medicaments can be pharmaceutical compositions or kits comprising compounds of the presently-described formula (I) or a salt, solvate or prodrug thereof. Specific compounds of the invention include 2-methyl-7-hydroxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran which is also known as BNC105 and disodium 6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzofuran-7-yl phosphate which is also known as BNC105P.

traducir

METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA

Publication No.: US2021177880A1 17/06/2021

Applicant:

HARVARD COLLEGE [US]
MASSACHUSETTS GEN HOSPITAL [US]

WO_2019089854_PA

Absstract of: US2021177880A1

The disclosure relates to compositions, methods, and kits for treating leukemia, specifically acute myeloid leukemia, in a subject, and for detecting chemoresistant acute myeloid leukemic cells.

traducir

INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 (BCL9) PROTEIN-PROTEIN INTERACTION

Publication No.: US2021179583A1 17/06/2021

Applicant:

H LEE MOFFTT CANCER CENTER AND RES INSTITUTE INC [US]

WO_2019118961_PA

Absstract of: US2021179583A1

Disclosed are inhibitors for the β-catenin/BCL9 interaction. The inhibitors are selective for β-catenin/BCL9 over β-catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

traducir

METHODS, REAGENTS AND KITS FOR DETECTING MINIMAL RESIDUAL DISEASE

Publication No.: US2021177936A1 17/06/2021

Applicant:

UNIV ERASMUS MED CT ROTTERDAM [NL]

AU_2018204429_A1

Absstract of: US2021177936A1

The invention relates to the field of minimal residual disease (MRD) diagnostics, which is progressively more applied for the evaluation of treatment effectiveness in patients with a hematological malignancy, such as B-cell precursor acute lymphoblastic leukemia (BCP-ALL), B-cell chronic lymphocytic leukemia (B-CLL), and multiple myeloma (MM). Provided are unique reagent compositions with carefully selected and thoroughly tested combinations of antibodies, for ≥8-color flow cytometric stainings as well as for 10-color and 12-color flow cyometric stainings, which can reach sensitivities of at least 10−4, even down to 10−5. Also provided are diagnostic kits and methods for detecting MRD.

traducir

GENOME EDITING OF GRAFT-DERIVED T-CELLS FOR POST-TRANSPLANT IMMUNOTHERAPY

Publication No.: US2021177899A1 17/06/2021

Applicant:

UNIV LELAND STANFORD JUNIOR [US]

Absstract of: US2021177899A1

Methods and compositions for modifying allogeneic donor αβ T cells for use in the treatment of high risk leukemias are provided.

traducir

Method of suppressing cancer by RNA m6A methyltransferase mettl16 inhibitors

Publication No.: GB2589912A 16/06/2021

Applicant:

CHEMESTMED LTD [EE]

Absstract of: GB2589912A

A pharmaceutical composition comprises a compound of formula (I) as defined herein, or a pharmaceutically effective salt thereof, and an excipient, for use in inhibiting RNA demethylation at the 6-position of adenine (m6A). Preferably the compound has formula (II), (III), (IV) or (V): The composition may be used in the treatment of glioblastoma, astrocytoma, acute myeloid leukemia, acute monocytic leukemia, chronic myelogenous leukemia, or T-acute lymphoblastic leukemia.

traducir

OPTICALLY ACTIVE BRIDGED PIPERIDINE DERIVATIVE

Publication No.: EP3835304A1 16/06/2021

Applicant:

SUMITOMO DAINIPPON PHARMA CO LTD [JP]

WO_2020032105_PA

Absstract of: EP3835304A1

The present invention relates to the compound of formula (1a) wherein a - d and p are 1 or 2, R<1> - R<4> are hydrogen atom or the like, and R<18> is -CF3 or the like, or a pharmaceutically acceptable salt thereof, which has an anticancer effect by inhibiting the binding between a MLL fusion protein that is fused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.

traducir

Methods for dosing and treatment of B cell malignancies in adoptive cell therapy

Publication No.: AU2019387494A1 10/06/2021

Applicant:

JUNO THERAPEUTICS INC

WO_2020113188_A2

Absstract of: AU2019387494A1

Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). In some embodiments, the methods are for treating subjects with relapsed or refractory CLL and SLL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.

traducir

Methods of dosing engineered T cells for the treatment of B cell malignancies

Publication No.: AU2019381827A1 10/06/2021

Applicant:

JUNO THERAPEUTICS INC

Absstract of: AU2019381827A1

Provided are methods for treatment and uses involving the administration of doses of engineered T cells for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The engineered cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL). In some embodiments, the subject is within a particular range of age, such as subjects that are 25 years or less of age, such as pediatric subjects.

traducir

Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations

Publication No.: AU2019387508A1 10/06/2021

Applicant:

APTOSE BIOSCIENCES INC

WO_2020113216_A1

Absstract of: AU2019387508A1

The present disclosure comprises a method for administering 2,3-dihydro-isoindole-1-one compound or a pharmaceutically acceptable salt, ester, solvate and/or prodrug thereof, alone or in combination with an anticancer agent, for the treatment of hematological cancers such as acute myeloid leukemia (AML). The present disclosure further relates to reducing or inhibiting mutated IDH1 activity in a subject.

traducir

DNA METHYLATION MARKERS FOR NONINVASIVE DETECTION OF CANCER AND USES THEREOF

Publication No.: US2021171617A1 10/06/2021

Applicant:

HKG EPITHERAPEUTICS LTD [CN]

KR_20210018189_PA

Absstract of: US2021171617A1

A “binary-categorical differentiation (BCD)” method for finding a combination of a small number (2-10) of exquisite DNA methylation positions in the human genome (CG IDs) for detecting cancer in DNA in biological material derived from a patient such as plasma, saliva, urine, feces, tissue biopsy, tissue swabs and tissue smears (such as pup smears) and distinguish it from other tissue cell free DNA and blood cells DNA. Another method for detecting tissue of origin of tumor DNA uses a combination of small number of unique DNA methylation positions in the human genome (CG IDs). Various novel combinations of CG IDs derived from tumor DNA are disclosed for detecting with high specificity and sensitivity a hepatocellular carcinoma (HCC), b. lung cancer, c. prostate cancer, d. breast cancer, e. colorectal cancer, f. pancreatic cancer, g. brain cancer (glioblastoma), h. gastric cancer i. ovarian cancer, j. cervical cancer k. head and neck squamous cell carcinoma (HNSC), l. esophageal cancer m. bladder cancer, n. renal cancer, o. testicular cancer, p. common solid tumors, q. blood cancers, r. acute myeloid leukemia (AML), s. melanoma by measuring the DNA methylation of a combination of specific CG IDs and deriving a “methylation score” disclosed herein. Kits for predicting cancer using CG IDs using multiplexed next generation sequencing methylation assays, pyrosequencing assays and methylation specific PCR from a small volume of plasma. Various methods using plasma, urine, fec

traducir

Methods of treating follicular lymphoma

Publication No.: AU2019388899A1 10/06/2021

Applicant:

JANSSEN BIOTECH INC

US_2020171034_A1

Absstract of: AU2019388899A1

Provided herein are methods of treating follicular lymphoma (FL) and gene mutations that can be used to predict a subject's nonresponsiveness to treatment of follicular lymphoma with ibrutinib.

traducir

SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS

Publication No.: US2021171566A1 10/06/2021

Applicant:

NUCANA PLC [GB]

JP_2021505578_A

Absstract of: US2021171566A1

The present invention relates to compounds comprising a salt of a diphosphate phosphoramidate of a nucleoside drug, e.g. clofarabine. The compounds are useful in the treatment of cancer, e.g. leukemia.

traducir

CHEMICAL COMPOUNDS

Publication No.: US2021171541A1 10/06/2021

Applicant:

ASTRAZENECA AB [SE]

TN_2017000486_A1

Absstract of: US2021171541A1

Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.

traducir

XBP1, CD138, AND CS1 PEPTIDES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE PEPTIDES, AND METHODS OF USING SUCH PEPTIDES AND COMPOSITIONS

Publication No.: US2021170004A1 10/06/2021

Applicant:

DANA FARBER CANCER INST INC [US]

AU_2021201265_A1

Absstract of: US2021170004A1

The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., breast cancer, colon cancer, pancreatic cancer, a blood cancer, e.g., leukemia or a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides (and pharmaceutical compositions comprising the peptides) can be used, e.g., in a method of treating a precancerous condition such as smoldering multiple myeloma. The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.

traducir

COMBINATION OF BCL-2 INHIBITOR AND MEK INHIBITOR FOR THE TREATMENT OF CANCER

Publication No.: US2021169865A1 10/06/2021

Applicant:

GENENTECH INC [US]
UNIV TEXAS [US]

MX_2018005233_A

Absstract of: US2021169865A1

The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.

traducir

USE OF MARIZOMIB FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) CANCERS

Publication No.: US2021169851A1 10/06/2021

Applicant:

CELGENE INT II SARL [CH]

JP_2020521719_A

Absstract of: US2021169851A1

The present disclosure relates to treatment of central nervous system (CNS) cancers (e.g., malignant glioma, glioblastoma, or CNS-multiple myeloma) using marizomib. The disclosure further relates to uses of synergistic combinations of marizomib with additional therapeutic agents such as bevacizumab, daratumumab, temozolomide, pomalidomide, and radiotherapy.

traducir

USE OF ISATUXIMAB FOR THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

Publication No.: US2021171653A1 10/06/2021

Applicant:

SANOFI AVENTIS US LLC [US]
SANOFI SA [FR]

Absstract of: US2021171653A1

The present disclosure provides methods for treating multiple myeloma (such as refractory multiple myeloma or relapsed and refractory multiple myeloma) in an individual who received one to three prior therapies (or prior lines of therapy) for multiple myeloma. The methods comprise administering to the individual an anti-CD38 antibody, carfilzomib, and dexamethasone.

traducir

METHODS OF ADMINISTERING ANTI-CD38 ANTIBODY

Publication No.: US2021171650A1 10/06/2021

Applicant:

SANOFI SA [FR]

TW_202108624_A

Absstract of: US2021171650A1

Provided are methods of treating a human individual having multiple myeloma that comprise administering to the individual 10 mg/kg isatuximab via intravenous infusion, wherein the volume of each infusion of 10 mg/kg isatuximab is 250 ml. Also provided are methods of treating a human individual having multiple myeloma that comprise administering an anti-CD38 antibody in 28-day cycles, wherein the anti-CD38 antibody is administered on Days 1, 8, 15, and 22 of a first 28-day cycle, wherein the CD38-antibody is administered on Days 1 and 15 of every 28-day cycle following the first 28-day cycle; and wherein the anti-CD38 antibody is administered at a dose of 10 mg/kg or 20 mg/kg.

traducir

METHODS OF TREATING MULTIPLE MYELOMA WITH BISPECIFIC ANTI-BCMA X ANTI-CD3 ANTIBODIES

Publication No.: WO2021113701A1 10/06/2021

Applicant:

REGENERON PHARMA [US]

Absstract of: WO2021113701A1

B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides methods for treating multiple myeloma using bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA.

traducir

METHODS RELATED TO TOXICITY AND RESPONSE ASSOCIATED WITH CELL THERAPY FOR TREATING B CELL MALIGNANCIES

Publication No.: WO2021113770A1 10/06/2021

Applicant:

JUNO THERAPEUTICS INC [US]

Absstract of: WO2021113770A1

Provided are methods for determining the risk of toxicity (e.g., neurotoxicity) and/or the likelihood of response to a cell therapy. In some aspects, the methods generally involve assessing parameters or biomarkers (e.g., blood analytes) that are associated with toxicity and/or response. In some aspects, the methods relate to adoptive cell therapy involving the administration of doses of cells for treating subjects with certain B cell malignancies, such as chronic lymphocytic leukemia (CLL), such as relapsed or refractory CLL, or small lymphocytic lymphoma (SLL). The cells for the adoptive cell therapy generally express recombinant receptors such as chimeric antigen receptors (CARs). In some aspects, the methods can be used to identify or select subjects for treatment, for example, with a cell therapy.

traducir

USE OF ISATUXIMAB FOR THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

Publication No.: WO2021113754A1 10/06/2021

Applicant:

SANOFI SA [FR]
SANOFI AVENTIS US LLC [US]

US_2021171653_A1

Absstract of: WO2021113754A1

The present disclosure provides methods for treating multiple myeloma (such as refractory multiple myeloma or relapsed and refractory multiple myeloma) in an individual who received one to three prior therapies (or prior lines of therapy) for multiple myeloma. The methods comprise administering to the individual an anti-CD38 antibody, carfilzomib, and dexamethasone.

traducir

FORMULATIONS OF ANTI-CD38 ANTIBODIES FOR SUBCUTANEOUS ADMINISTRATION

Publication No.: WO2021113739A1 10/06/2021

Applicant:

BALLET THOMAS [US]
BANGARI KIRAN [US]
CHARI RAVI [US]
HUILLE SYLVAIN [FR]
PEREZ RAMIREZ BERNARDO [US]
VASCO FILIPE [US]

Absstract of: WO2021113739A1

Provided are formulations of anti-CD38 antibodies suitable for subcutaneous administration to a subject in need thereof. The formulations include a high concentration of antibody, a viscosity lowering agent, a stabilizing agent, a buffering agent and a surfactant. In certain embodiments, the viscosity of the solution is at most 25 mPa·s, and the pH of the solution is 5.9 to 7.0. In certain embodiments, the anti-CD38 antibody is isatuximab. The formulations will find use in treating CD38+ hematological malignancies, including multiple myeloma, as well as autoimmune and inflammatory diseases, in humans.

traducir

COMBINATION THERAPIES FOR TREATMENT OF MYELODYSPLASTIC SYNDROME

Nº publicación: WO2021113688A1 10/06/2021

Applicant:

SUMITOMO DAINIPPON PHARMA ONCOLOGY INC [US]

Absstract of: WO2021113688A1

The present invention relates to methods for treatment of myelodysplastic syndrome (MDS) by administration of a hypomethylating agent (HMA), such as azacitidine or decitabine, or a prodrug of either of the foregoing, or a pharmaceutically acceptable salt of any of the foregoing, and alvocidib, or a prodrug thereof, or a pharmaceutically acceptable salt of the foregoing.

traducir

Page1/4 nextPage results/page

punteroimgGo back